Ceapro Extends Exclusive International Supply and Distribution Agreement with Leading Global Provider of Active Ingredients, Symrise
EDMONTON, Alberta, Aug. 25, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced the signing of an amendment to its long-term agreement with German-based multinational, Symrise AG, for the distribution and commercialization of Ceapro’s high value active ingredients to major key international players in the cosmetic market. The three-year agreement, signed on January 1, 2022, will now extend until December 31, 2026.